Uses of sysnergistic bacteriophage lytic enzymes for prevention and treatment of bacterial infections
First Claim
1. A method of treating or preventing bacterial infections, comprising administering to a subject in need of such therapy a therapeutically effective amount of a synergistic combination of:
- (a) at least two bacteriophage derived lytic enzymes; and
(b) a suitable carrier for delivery of the lytic enzymes to the site of infection.
1 Assignment
0 Petitions
Accused Products
Abstract
Methods for treating and preventing bacterial infections are described using at least two lytic enzymes obtained from a bacteriophage isolated from Streptococci. Two of these enzymes, Pal and Cpl-1, showed synergy when tested for cleavage of peptidoglycan in the cell walls of Streptococcus pneumoniae. Moreover, the combination of these two enzymes resulted in killing of both penicillin sensitive as well as penicillin resistant strains of S. pneumoniae. The synergy displayed by the combined use of these two enzymes may establish a means for identification of agents that mimic or enhance this activity and may lead to the identification of new antimicrobial agents and pharmaceutical compositions useful for treating and preventing a variety of bacterial infections in mammals. Further compositions are described for disinfecting or sanitizing porous and non-porous surfaces suspected of harboring infectious organisms.
5 Citations
29 Claims
-
1. A method of treating or preventing bacterial infections, comprising administering to a subject in need of such therapy a therapeutically effective amount of a synergistic combination of:
-
(a) at least two bacteriophage derived lytic enzymes; and
(b) a suitable carrier for delivery of the lytic enzymes to the site of infection. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 13)
-
- 11. A method of treating or preventing bacterial infections, comprising administering to a subject in need of such therapy a therapeutically effective amount of bacteriophage derived lytic enzymes selected from the group consisting of an amidase, a muramidase, an endopeptidase, a glucosaminidase, and synergistic combinations thereof.
-
15. A pharmaceutical composition comprising:
-
(a) at least two therapeutically effective synergistic bacteriophage derived lytic enzymes; and
(b) a carrier suitable for delivery of the lytic enzymes to the site of infection. - View Dependent Claims (16, 17)
-
-
18. A screening method for identifying agents capable of enhancing the activity of Pal and Cpl-1, comprising:
-
(a) preparing purified Pal and Cpl-1;
(b) contacting the Pal and Cpl-1 to a bacteria having radioactively labeled peptidoglycan in the cell wall in the presence or absence of a test compound under conditions which allow binding to the peptidoglycan; and
(c) determining the amount of peptidoglycan cleavage, wherein an agent capable of enhancing Pal and Cpl-1 activity is identified when the release of radioactivity is enhanced in the presence but not the absence of the agent.
-
- 19. An anti-microbial composition for sanitizing or decontaminating porous or non-porous surfaces comprising at least two bacteriophage derived synergistic lytic enzymes.
-
25. (canceled)
-
26. (canceled)
-
27. (canceled)
-
28. (canceled)
-
29. (canceled)
Specification